EPIC: Balloon Angioplasty

Slides:

Advertisements

Similar presentations

Rabih R. Azar, MD, MSc, FACC Director of Cardiovascular Research Hotel Dieu de France Hospital Associate Professor of Medicine Saint Joseph University.

Advertisements

Stone p2203/Abstract/ Conclusions

Stent Parameters Predict Major Adverse Clinical Events and the Response to Platelet Glycoprotein IIb/IIIa Blockade Findings of the ESPRIT Trial James E.

Update on the Medical Management of Acute Coronary Syndrome.

The Evolving Role of LMWH in ACS James J. Ferguson, MD Texas Heart Institute Houston, TX James J. Ferguson, MD Texas Heart Institute Houston, TX.

Clinical Trials of GP IIb/IIIa Inhibition Major Trials of GP IIb/IIIa Inhibitors in ACS GP IIb/IIIa Inhibitors in PCI GP IIb/IIIa Inhibition in Patients.

RE-MEDY Cumulative Risk Recurrent Venous Thromboembolism or Related Death in the Active-Control Study Months since Randomization Estimated Cumulative Risk.

Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.

ISAR-REACT 4: Discussion Deepak L. Bhatt MD, MPH, FACC, FAHA Chief of Cardiology, VA Boston Healthcare System Director, Integrated Interventional Cardiovascular.

Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.

ReoPro ® in NSTEMI and STEMI Trials Harald Vangerow, MD Clinical Research Physician Eli Lilly UK.

Www. Clinical trial results.org Unfractionated heparin 60 U/kg bolus, then 12 U/kg per hour adjusted to an activated partial thromboplastin time of 50.

High-Dose, Double-Bolus Eptifibatide (Integrilin™) in Non- Urgent Coronary Stent Intervention 6 Month Results of the ESPRIT Trial.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

1 Advanced Angioplasty London, England 27 January, 2006 Jörg Michael Rustige,MD Medical Director Lilly Critical Care Europe, Geneva.

Relative Risk Therapy A Better Therapy B Better COMPASS 95% CI no worse than 1.5 TARGET 95% CI no worse than 1.47 ASSENT-2.

OASIS-2 OASIS-2 OVERVIEW 10,141 patients evaluating Hirudin vs. Heparin and 3712 patients evaluating Warfarin vs. Standard Therapy International (16 Countries)

ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.

GUSTO IV ACS: Trial Design Abciximab versus placebo in very high-risk patients with non-ST elevation acute coronary syndromes: – ST  > 0.5 mm or – elevated.

NSTE Acute Coronary Syndromes

VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.

NICE-3 National Investigators Collaborating on Enoxaparin XXII nd Congress of the European Society of Cardiology August 30, 2000 Amsterdam, The Netherlands.

CAPTURE: C 7E3 Fab A nti- P latelet T herapy in U nstable RE fractory Angina ¤ Study Population:Patients with chest pain at rest and ECG signs of UA (NQMI.

Equivalence Trials: Understanding the Statistical and Clinical Issues Christopher Cannon, M.D. C. Michael Gibson, M.S., M.D. Brigham and Women’s HospitalBeth.

AHA 2011 Late Breaking Trials Synthesis and Critical Review.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship between heparin anticoagulation and.

1 Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial N Engl J Med 2001;344:

Tirofiban Meta-Analysis

The American College of Cardiology Presented by Dr. Adnan Kastrati

MCV Campus Ginger Edwards.

Bivalirudin is Superior to Heparin for ACS Patients

PRAGUE-18 Trial design: Patients with STEMI undergoing primary PCI were randomized to prasugrel (n = 634) versus ticagrelor (n = 596). Results (p = 0.94)

TAXUS II: Slow Release Formula An International, Randomized, Multicenter, Blinded Trial of TAXUSTM NIRxTM SR Stent Presented at TCT 2002.

M. Valgimigli University of Ferrara Italy

FINESSE: Study Design Acute ST Elevation MI (or New LBBB) within 6h pain onset Presenting at Hub or Spoke with estimated time to Cath between 1 and 4 hours.

HOPE: Heart Outcomes Prevention Evaluation study

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

The European Society of Cardiology Presented by Dr. Saman Rasoul

Study Design AMI <12 hours, any age, cardiogenic shock excluded

Valsartan in Acute Myocardial Infarction Trial Investigators

Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.

ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.

LEVO-CTS Trial design: Patients undergoing cardiac surgery with the use of cardiopulmonary bypass were randomized to infusion of levosimendan 0.2 µg/kg/min.

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

Late Breaking Clinical Trials

European Society of Cardiology 2003

GUSTO-IV ACS GUSTO IV ACS evaluated the safety and efficacy of abciximab given as first line medical therapy in a broad population of patients with non-ST.

TAXUS II: Moderate Release Formula An International, Randomized, Multicenter, Blinded Trial of TAXUSTM NIRxTM MR Stent Presented at TCT 2002.

The HORIZONS-AMI Trial

Probability of No Urgent Repeated Percutaneous Revascularization Procedures in the Three Treatment Groups (Kaplan-Meier Plots) Figure 1. Probability of.

Published in the European Heart Journal

ARNO TRIAL (Antithrombotic Regimens aNd Outcome)

Randomized Comparison in the Setting of Acute MI

The ESPRIT Trial 6 Month and 1 Year Results

American Heart Association Presented by Dr. Julinda Mehilli

American College of Cardiology Presented by Dr. Michel R. Le May

Erasmus MC, Thoraxcenter

AGENT III: 12 week results

Drug-eluting stents for in-stent restenosis

Role of Stenting in Acute MI: PAMI Stent Pilot Trial

Clinical Trial Commentary

Elevated Admission Plasma Glucose Following ACS

EPILOG Results: Balloon Angioplasty/Bail-out Stenting

Overall (n=301) Acute/Subacute (n=149) Late (n=152) p Presentation

Efficacy and Safety of Fondaparinux in Elderly Patients With ST-Segment Elevation Myocardial Infarction: Data From the OASIS 6 Trial Ron J.G. Peters,

OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)

IMPACT II Results: Balloon Angioplasty/Bail-out Stenting

For the HORIZONS AMI Investigators

INTRO AMI. INTEGRILIN AND. REDUCED DOSE. OF THROMBOLYTIC IN. ACUTE

FIELD: Primary outcome

Presentation transcript:

EPIC: Balloon Angioplasty Primary Endpoint: Death, MI, UTVR at 30 days Placebo + heparin (ACT  300 sec) (n=696) Abciximab 0.25mg/kg bolus + heparin (ACT  300 sec) (n=395) Abciximab 0.25mg/kg bolus / 10 µg/kg infusion + heparin (ACT  300 sec) (n=708) 4.5%  (P<0.004) 1.4%  (P=ns) % events 12.8% 11.4% 8.3% The EPIC investigators. N. Engl J Med. 1994; 330: 956-961.

EPIC Results 30 Day Death/MI 3.5%  (P=0.015) 6 Month Death/MI 3.9%  (P=0.019) 30 Day TVR 3.8%  (P=0.003) 6 Month TVR 5.8%  (P=0.007) 9.6% 6.1% 12.8% 8.9% 7.8% 4.0% 22.3% 16.5% 1.4% 6.6% Major TIMI Bleeding Placebo + heparin (ACT  300 sec) (n=696) Abciximab + heparin (ACT  300 sec) (n=708) % events The EPIC investigators. N. Engl J Med. 1994; 330: 956-961.